TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7842184
Drug: Intranasal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal triamcinolone acetonide
Study: 22807519
Drug: Balapiravir 1500
Normalized name: Balapiravir
DrugBank: Balapiravir (DB12283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balapiravir 1500 mg
Study: 18074664
Drug: Esomeprazole magnesium
Normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole magnesium 40 mg once daily for 2 to 12 months
Study: 27183546
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (FAc) implants
Study: 9761130
Drug: I2 (iodine)
Normalized name: I2
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I2 (iodine) at doses of 0.3 or 1 mg/kg body weight
Study: 29571953
Drug: Control injection
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injection of sterile saline water
Study: 29268139
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 plus carboplatin AUC4
Study: 23949578
Drug: Albuterol administration
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administration (mean 12.3 mg prior to baseline)
Study: 14516877
Drug: trapidil 100
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trapidil 100 mg 3 times daily
Study: 28810024
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (n=64) including 5 to 6 weekly aerobic training sessions (30-60 minutes) and dietary plans aiming for a BMI of 25 or less.
Study: 8172701
Drug: Proposed evaluation
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed evaluation method for treatment of otitis media
Study: 25434320
Drug: Drotaverine hydrochloride
Normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine hydrochloride 80 mg tablet given thrice a day
Study: 28371204
Drug: Bland dimethicone-based
Normalized name: Dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bland dimethicone-based ointment and petrolatum-based cream
Study: 23748114
Drug: Fulranumab 10
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 10 mg every 8 weeks (Q8wk)
Study: 25708866
Drug: niacin 6000
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin 6000 mg/day
Study: 18595523
Drug: Aerius 5
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerius 5 mg/d for 12 days
Study: 16738858
Drug: Sham subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham subconjunctival injection
Study: 12095806
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without treatment (63 patients)
Study: 26806605
Drug: SQ BNP
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SQ BNP 10 µg/kg, twice-daily for 12 weeks
Study: 19029093
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose followed by bolus (0.06+0.94 mg kg(‐1))
Study: 25268567
Drug: Low-dose progesterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose progesterone (PG)
Study: 28104702
Drug: IL-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IL-2 treatment
Study: 20130094
Drug: Low-dose DHA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DHA (400 mg/d)
Study: 17197130
Drug: Adequate RT
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate RT (minimum radiation dose delivered: 4300 cGy for neoadjuvant RT or 4700 cGy for adjuvant RT; completion of RT in <44 days for neoadjuvant RT or <49 days for adjuvant RT)
Study: 8807068
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ciprofloxacin and clarithromycin)
Study: 11427639
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg)
Study: 9587911
Drug: Chronic exposure
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic exposure to carbon disulfide (9.36‐23.4 mg/m2)
Study: 22852579
Drug: Org 26576
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 26576 at 450 mg bid in MDD patients
Study: 20458090
Drug: Cholecalciferol treatment
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol treatment (800 IU/d)
Study: 7105431
Drug: L-dopa plus
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa plus carbidopa (250 mg and 25 mg respectively every 6 h for 1 day)
Study: 26525809
Drug: Axamon (ipidacrine)
Normalized name: ipidacrine
DrugBank: Ipidacrine (DB13668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axamon (ipidacrine) in addition to basic therapy (B vitamins, lipoic acid) for 6 weeks
Study: 18753749
Drug: Restorations without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Restorations without leakage (L-) with fluoride dentifrice (FD)
Study: 20039090
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) algorithm-guided antibiotic therapy
Study: 19111473
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/(m2 12 h), days 1‐14 plus oxaliplatin 130 mg/m2 day 1, every 3 weeks
Study: 8200260
Drug: Interferon-alpha 2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha 2a therapy
Study: 29194531
Drug: Radical rectal
Normalized name: Radicava
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radical rectal surgery (segmental resection)
Study: 12846615
Drug: Low-dose bupivacaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bupivacaine 4 mg with 25 micro g of fentanyl
Study: 29348651
Drug: MDMA 75
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 75 mg
Study: 28525555
Drug: Baclofen 180
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 180 mg/day
Study: 12575905
Drug: SUCROSE diet
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SUCROSE diet (high carbohydrate increase of 90 g sucrose/d)
Study: 29570535
Drug: Testosterone supplementation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone supplementation with testosterone enanthate injections at 2-week intervals during bed rest
Study: 10783450
Drug: Lignocaine gel
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine gel alone
Study: 6364951
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin
Study: 27658130
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (2.4 g daily for 1 month)
Study: 24793938
Drug: BPZE1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPZE1 vaccine
Study: 25472768
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (basal-bolus)
Study: 15053895
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (single dose)
Study: 30922276
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone
Study: 19951555
Drug: Glutamine-enriched enteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched enteral nutrition (0.5 g x kg(‐1) x d(‐1))
Study: 8503339
Drug: Flutamide 90
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 90 mg/day
Study: 8610768
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (transdermal or oral)
Study: 31505542
Drug: l-DOPA
Normalized name: L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: l-DOPA
Study: 25920500
Drug: Budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide MMX 9 mg
Study: 23436336
Drug: Budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide MMX 6 mg
Study: 29154068
Drug: Yoga home-exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga home-exercise (10min daily)
Study: 10414910
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration on day +1 (group B)
Study: 31313549
Drug: Vancomycin hydrochloride
Normalized name: Vancomycin Hydrochloride
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin hydrochloride 1000 mg BD
Study: 23663488
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 100 μg, 1 spray/nostril QD for 4 weeks
Study: 30076173
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin 3 mg/m2 on days 1, 4, and 7 during induction and 3 mg/m2/day on day 1 during consolidation
Study: 9095813
Drug: Low-air loss
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-air loss (LAL) therapy
Study: 28338531
Drug: Oral Contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptives
Study: 25248797
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (weekly trainer-led group exercise sessions, instructed home exercise 3-5 times/week during 20-36 weeks of gestation, dietary counseling twice during pregnancy)
Study: 11789241
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy using Jiangtang Janshenling (JTJSL) capsule, alongside western medicine for blood glucose control, for three months.
Study: 2144260
Drug: UK 79300
Normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 79300 (25 or 50 mg p.o.)
Study: 18777156
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Aspart
Study: 24002929
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (high dose): 0.25 mg/kg/min (1 min) loading followed by 0.04 mg/kg/min (20 min) continuous infusion
Study: 27689944
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (0.67 mg/m2/day)
Study: 7788682
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (ACE inhibitor) for six weeks
Study: 26939318
Drug: Fire-needle treatment
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire-needle treatment
Study: 20880870
Drug: Cylinder air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylinder air provided at 6 l/min intranasally during activities provoking breathlessness
Study: 2473539
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Iloprost
Study: 24389433
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² and carboplatin (AUC 6 mg/min/ml) plus panitumumab (2.5 mg/kg)
Study: 25637294
Drug: Intra-aortic balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic balloon pump (IABP) in addition to optimal medical therapy (OMT)
Study: 25050589
Drug: Submicron diclofenac
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Submicron diclofenac 35 mg bid
Study: 10801249
Drug: Enteric-coated methylnaltrexone
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated methylnaltrexone (3.2 mg/kg) after morphine
Study: 1827213
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide delivered by metered-dose aerosol plus spacer and mask (MDA group)
Study: 8014496
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ganciclovir-foscarnet)
Study: 29658258
Drug: Oral Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Levofloxacin only
Study: 30482480
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly
Study: 25146070
Drug: Spa adjuvant
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa adjuvant therapy
Study: 17023233
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR (Controlled-Release)
Study: 21033121
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) for tennis elbow
Study: 20490798
Drug: Etoposide and
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide and carboplatin infusions
Study: 3279857
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion (three doses)
Study: 10617985
Drug: High-DHA eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-DHA eggs (170-260 mg/d)
Study: 16724993
Drug: H(2)-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H(2)-receptor antagonist half-dose group
Study: 16724993
Drug: H(2)-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H(2)-receptor antagonist full-dose group
Study: 25414152
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for mild GDM
Study: 17597643
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk containing Lactobacillus casei (100 mL, 10^8 cfu/mL)
Study: 29048352
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei Shirota (LcS) in fermented milk (6.5 × 10⁸ cfu) daily for 8 weeks
Study: 30044938
Drug: BCX7353 250
Normalized name: BCX7353
DrugBank: Berotralstat (DB15982)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCX7353 250 mg
Study: 31776782
Drug: WLS Optimum
Normalized name: WL-1002
DrugBank: WL-1002 (DB05346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WLS Optimum (specialized multivitamin supplement)
Study: 21865944
Drug: Aggressive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive glycemic control (90‐120 mg/dL)
Study: 9014544
Drug: Manual infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual infusion of propofol at 1200 ml.h‐1
Study: 9014544
Drug: Manual infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual infusion of propofol at 600 ml.h‐1
Study: 29613944
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (10-Hz stimulation, 20 daily treatments)
Study: 26680374
Drug: Heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme arginate (HA) 3 mg/kg
Study: 8993241
Drug: Aprotinin (high-dose)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (high-dose)
Study: 30246883
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (weight reduction diet + bolus weekly dose of 50,000 IU vitamin D)
Study: 8774217
Drug: Guar wheatflake
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar wheatflake meal (6.3 g guar gum)
Study: 27789350
Drug: DMPA 104
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA 104 mg
Study: 15294061
Drug: Inhalation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation without noseclip
Study: 25057981
Drug: Investigative CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigative CT protocol with iterative reconstruction at conventional radiography dose levels
Study: 30570787
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with high-dose hypoallergenic birch pollen allergoid
Study: 8577017
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN) at day 1, n = 4
Study: 19995098
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid 135 mg + moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, atorvastatin 40 mg)
Study: 21808751
Drug: Olanzapine ODT
Normalized name: Olanzapine Orally Disintegrating Tablets
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine ODT (10 to 20 mg, once daily)
Study: 15111514
Drug: Human Premix
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Premix Insulin (MIX)
Study: 29457540
Drug: CD34+ mononuclear
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ mononuclear cell therapy (CD34+MCT)
Study: 7863489
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (250 mg/kg)
Study: 31972657
Drug: Remimazolam continuous
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam continuous IV infusion at 5 mg/min for 5 min, 3 mg/min for 15 min, and 1 mg/min for 15 min
Study: 30414260
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla‐300)
Study: 25840429
Drug: Administration route
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration route and priming time interaction
Study: 30182858
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 5-10 mg TID
Study: 24786925
Drug: Abatacept (ABA)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept (ABA) treatment
Study: 29998337
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase at standard dose (0.9 mg/kg) with oral placebo (n=156)
Study: 7864418
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.75, 1.5, and 3 mg/70 kg)
Study: 10404804
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 5 mg